Author

Jennifer B. Dennison

The University of Texas MD Anderson Cancer CenterORCID 0000-0003-3067-0972Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:metabolomics· 2 Assay:proteomics· 2

Frequent Co-Authors

Ehsan IrajizadiD· 3 shared Fu Chung Hsiao· 3 shared Hiroyuki KatayamaiD· 3 shared Jody Vykoukal· 3 shared Johannes Francois FahrmanniD· 3 shared Ricardo A. Léon-LetelieriD· 3 shared Samir HanashiD· 3 shared Yining Cai· 3 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Ehsan IrajizadORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 6, 2026

KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adenocarcinoma

Yihui Chen, Cason Haffner, Benson Chellakkan Selvanesan…·Johannes Francois Fahrmann

This study identifies KRAS-driven metabolic reprogramming through MFSD2A-mediated lysophosphatidylcholine scavenging as a driver of PDAC progression and shows that targeting this pathway with edelfosine has anti-cancer effects.

DOI 10.64898/2026.10.05.756824

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCell Reports MedicinePeer-reviewedDec 1, 2025

Vesicle-mediated mitochondrial clearance underlies an actionable metabolic vulnerability in triple-negative breast cancer

Jody Vykoukal, Yihui Chen, Mingxin Zuo…·Johannes Francois Fahrmann

The paper identifies a metabolic vulnerability in triple-negative breast cancer through sphingolipid metabolism, showing that targeting this pathway with eliglustat reduces tumor growth and improves survival.

6 citations

mouseproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 7, 2024

Aberrant expression of CD14 in breast tumor cells is associated with poor outcome

Hiroyuki Katayama, Rongzhang Dou, Ricardo A. Léon-Letelier…·Samir Hanash

This study identifies aberrant CD14 expression in breast tumor cells as a marker of poor clinical outcomes and aggressive disease.

1 citation

humanproteomics

𝕏 PostBluesky